Management of Noradrenaline and Octreotide in Upper GI Bleeding with Shock

Pharmacologic Management in Upper GI Bleeding

The American College of Physicians recommends that octreotide is not used for routine management of acute nonvariceal upper GI bleeding, as evidenced by studies from 2003 and 2019 1, 2
Octreotide may be beneficial for patients with upper GI bleeding who are bleeding uncontrollably while awaiting endoscopy, with a favorable safety profile in the acute setting 1, 3
The American College of Physicians suggests that octreotide can be used for patients with nonvariceal bleeding who are awaiting surgery or for whom surgery is contraindicated, due to its ability to reduce splanchnic blood flow 1, 3

The Society of Critical Care Medicine indicates that vasopressors such as noradrenaline are used for hemodynamic support in shock states, with no contraindications to using noradrenaline concurrently with octreotide in the management of shock associated with GI bleeding 1, 4
Noradrenaline primarily supports blood pressure and tissue perfusion, while octreotide reduces splanchnic blood flow, potentially decreasing bleeding 2

The American College of Physicians recommends resuscitation with fluid replacement and blood products as needed, followed by the initiation of noradrenaline for hemodynamic support if shock persists despite fluid resuscitation 2, 4
Octreotide can be considered in cases of uncontrollable bleeding while awaiting endoscopy, or for patients awaiting surgery or when surgery is contraindicated, typically administered as a 50-100 μg bolus followed by 25-50 μg/hour infusion 1, 3
Urgent endoscopy should be arranged within 12 hours of presentation, and high-dose proton pump inhibitor therapy should be administered 2, 4
Close monitoring is essential for hemodynamic parameters, cardiac effects, and continued bleeding or rebleeding 4